HeartFlow Inc's stock surged 9.72% during intraday trading on Wednesday, following a significant company announcement.
The sharp rise appears to be driven by the company's update on its NAVIGATE-PCI Registry clinical study. HeartFlow announced new developments in its data pathway for AI-guided stent planning, which investors likely viewed as a positive advancement for the company's medical technology platform.